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The aim of this study was to evaluate the effectiveness of interventions used for improving 
ADR reporting by patients and healthcare professionals. 
 
Areas covered  
A systematic review of literature was conducted by searching Medline, Embase and 
Cochrane Central Register of Controlled of Trials. Meta-analysis of randomised controlled 
trials (RCTs; n=5) was conducted to estimate the pooled risk ratio for the effectiveness of 
interventions on ADR reporting rates. Data from observational studies were synthesised 
using narrative synthesis approach.  
 
Expert Opinion 
A total of 28 studies were included. All except one study targeted healthcare professionals 
using educational, technological, policy, financial and/or mixed interventions. The results 
showed that financial and face-to-face educational interventions improved quality and 
quantity of ADR reporting when compared with interventions not involving face-to-face 
interactions. However, the quality of studies was generally low. Meta-analysis showed a 
statistically significant 3.5-fold overall increase in reporting of ADRs [RR 3.53; 95% CI 
(1.77,7.06)] in the intervention group compared to the control. There was a lack of 
consideration of theory and sustainability in the design of the interventions. There is a 
need to develop and test theory-based interventions and target patient reporting. More 
research needs to be conducted in the low-and-middle-income countries.  
 
Study protocol:  




 It is known that up to 94% of adverse drug reactions (ADR) are not reported. 
Under-reporting delays drug safety signals compromising patient safety. 
 There is lack of high-quality interventions that aim to increase ADR reporting. 
 Limited evidence suggests face-to-face education interventions combined with 
financial incentives tend to increase ADR reporting by healthcare professionals. 
 This systematic review identifies lack of interventions targeted at patients to 
improve ADR reporting. 
 More research studies are needed in low-and-middle-income countries. 
 




This systematic review and meta-analysis conform to the PRISMA reporting guideline. A 
PRISMA checklist has been provided as an electronic supplementary material. 
  
1.0 INTRODUCTION 
When a drug is introduced to the market, its safety profile is poorly understood, and the 
spontaneous reporting of adverse reactions remains an essential element for the 
dissemination of safety signals. An adverse drug reaction (ADR), as defined by the World 
Health Organisation is 'a response to a drug which is noxious and unintended, and which 
occurs at doses normally used in humans for the prophylaxis, diagnosis, or therapy of 
disease, or for the modifications of physiological function' [1]. ADRs are responsible for 
unplanned hospital admissions and mortality, with elderly and children most likely to suffer 
ADRs. It is estimated that approximately 1 in 10 admissions of older persons are due to 
ADRs [2]. There are also economic consequences to the healthcare system. It was 
reported that ADRs costs the European Union member states and the US approximately 
€79 billion [3] and $30 billion [4] annually respectively. 
 
One of the main limitations of the spontaneous reporting system of ADRs is under-
reporting. A recent systematic review of 37 studies across 12 countries showed that the 
median under-reporting rate was 94% [5]. Under-reporting delays drug safety signals 
compromising abilities of national pharmacovigilance centres to generate drug safety 
signals. Numerous factors contribute to underreporting of ADRs, which include: lack of 
awareness for the purpose of ADR monitoring and reporting, lack of knowledge on how to 
use spontaneous reporting of ADRs, restricted access to reporting tools, uncertainty in 
ADRs associated with many drugs, time constrictions on healthcare professionals and 
patients, bias due to intensive media coverage of some ADRs, and failure to verify 
diagnostics reported increases data restriction [6,7].  
 
Pharmacovigilance is an umbrella term encapsulating the systematic detection, reporting, 
assessment, understanding and prevention of ADRs [8]. Effective and efficient 
pharmacovigilance systems provide surveillance of marketed medicines, thus are essential 
to protect the health of the public and limit healthcare costs caused by ADR-related 
complications. Globally, post-marketing surveillance of medicines is mainly coordinated by 
national pharmacovigilance centres responsible for collecting and analysing reports of 
ADRs, making decisions based on the analysis of the reports and alerting prescribers, 
manufacturers and the public to new risks of ADRs.  
 
The aim of this study was to evaluate the effectiveness of interventions to improve the 
quantity and quality of spontaneous reporting of ADRs amongst both patients and 
healthcare professionals. This study will update the evidence presented in a previous 
systematic review on the topic area [9] which considered published literature until 2010. 
In addition, the previous review did not consider meta-analysis in their approach to 
evidence synthesis. Given evolving international pharmacovigilance regulations, practices 
and increased emphasis on patient reporting of ADRs, there is a need to update the review 
to provide researchers, practitioners and stakeholders with up-to-date evidence on the 
nature and effectiveness of pharmacovigilance interventions.    
 
The primary outcome of the study was the quantity of ADRs reported as a result of the 
intervention including improvement in the number or rate of reporting. Secondary 
outcome included the quality of ADR reporting including the nature of ADRs reported (e.g. 





This study adhered to Cochrane guidelines [10] and Preferred Reporting Items for 
Systematic Review and Meta-Analysis reporting guidelines (PRISMA) [11] to conduct and 
report the review respectively. A protocol was prepared using Preferred Reporting Items 
for Systematic Review and Meta-Analysis Protocols (PRISMA-P, CRD42019162209) [12]. 
An electronic search of MEDLINE, EMBASE, and Cochrane trials register databases were 
undertaken using Medical Subject Headings (MeSH) and natural language key words, 
Boolean operators, truncations (*) and wild cards ($). A search strategy using keywords 
and Medical Subject Headings was utilised to perform a search (online resource- 
supplementary material 1). The reference lists of included studies were hand searched to 
identify any additional references for inclusion. In particular we considered all references 
within a previous systematic review [9] conducted on the same topic.   
 
2.2 Eligibility criteria 
No restrictions to country of origin, publication language was applied. All forms of 
interventional designs were considered. Literature from year 2000 till August 2019 that 
sought to improve either a) quality or b) quantity or both of spontaneous ADR reporting 
were included. Educational research with student participants, interventions not including 
qualified healthcare practitioners or patients were excluded as well as the interventions 
related to devices and planned ADR surveillance monitoring programmes, such as those 
used for mass vaccinations. Abstract only publications including conference abstracts were 
excluded. 
 
2.3 Screening and selection 
Screening was conducted by one pair of researchers (VP, DS; VP, AH) acting independently 
in three consecutive stages: screening of titles; screening of abstracts; screening of full 
text against the eligibility criteria.  
 
2.4 Data extraction and quality assessment 
A data extraction form was developed based on the review aim, refined, reviewed and 
piloted. Cochrane risk of bias tool for Randomised Controlled Trials [13] and The Critical 
Appraisal Skills Programme (CASP) quality assessment tool for cohort study (for all other 
study designs) was used to assess study quality [14].  
 
2.5 Data Synthesis 
The technique for data synthesis varied across different study designs. Data from RCTs 
(n=5) were combined using random effects meta-analysis. We reported pooled risk ratio 
(95% CI) to demonstrate the effectiveness of interventions to improve the quantity, i.e. 
rate of ADR reporting. Relative risk data adjusted for duration of follow-up was extracted 
and used in meta-analysis, if reported in individual studies. In instances, where the 
effectiveness of intervention was tested at multiple time-points and time-adjusted relative 
risk was not reported, the relative risk for last follow-up time point was extracted. Forest 
plots were produced using RevMan®.  Forest plots refer to graphical representation of 
individual studies in a meta-analysis and allow researchers to graphically identify whether 
the cumulative evidence in relation to effectiveness of interventions under study favours 
control or experimental group [15]. In relation to the impact on the quality of ADR 
reporting, it was not possible conduct a meta-analysis due to heterogeneity in the 
definition and lack of clarity around seriousness of ADRs and completeness of ADRs.  
 
We did not undertake meta-analysis for non-randomised controlled studies, due to the 
presence of confounding factors that could affect overall findings and introduce bias [16]. 
Therefore, a narrative synthesis of the outcomes was undertaken using summary tables 
extracting data on the rate and quality of ADR reporting. 
 
3.0 Results 
A total of 6812 unique titles were screened, of which 28 studies [17-44] fulfilled eligibility 
criteria for inclusion in the review (online resource- supplementary material 2). Most 
studies originated from Portugal n=5), followed by Sweden (n=4) and Spain (n=4) (table 
1). Only seven of the studies used a randomised controlled design of which five studies 
used cluster randomisation design. The rest were either quasi experimental, observational 
pre-post or time series analysis (table 1). All studies focused on healthcare professionals 
apart from one study in the UK which also focused on general members of the public. The 
study focused on patients [22] aimed to assess patterns in reporting of ADRs via the Yellow 
Card Scheme following a Scottish community pharmacy patient Yellow Card promotional 
campaign (table 1). A mix of healthcare professionals in various settings was targeted by 
other studies including physicians, nurses and pharmacists. Four studies exclusively 
targeted pharmacists (table 1).  
 
3.1 Risk of bias within RCTs 
High risk of bias was identified for most of the domains for the included studies (figure 1, 
online resource- supplementary material 3). In particular, allocation concealment 
(selection bias), blinding of participants and personnel (performance bias) was not 
discussed sufficiently in any of the seven trials to allow a judgement [25,27,30,31,34, 
38,40]. Therefore, there was insufficient information to permit judgment of high or low 
risk. Selection bias in relation to random sequence generation was high in two studies 
[30,34] as allocation was by the availability of the intervention and this information was 
unclear in another study [25]. Contamination between the intervention and control groups 
could not be ruled out in all of the seven RCTs. 
 
Overall, the quality of the non-randomised studies was also considered to be low. Fourteen 
studies did not include a control group in their study design and where a  control group 
was used, it was often not clear whether the nature of likely ADRs to be reported were 
identical across both groups in relation to clinical settings and patient demography (online 
resource- supplemental material 4). There was a general lack of consideration about what 
factors other than the interventions i.e. confounding factors during the study may have 
impacted on the observed changes. Development and validation of data collection tools 
were poorly described. Follow up lacked adequate lag time in studies particularly those 
adopting educational interventions as evaluation often measured transient impact on 
knowledge and practice. Sample size of participants or the report numbers were often low 
compromising the generalisability of the findings.  
 
A lack of standardised definition and classifications of ADRs were observed in the included 
studies. Classification systems were based on seriousness (serious and non-serious), 
whether expected and unexpected, and whether labelled and unlabelled (table 1).  
 
 
Table 1 to appear here 
 
3.2 Nature of interventions 
Educational interventions 
Twenty-one studies implemented educational interventions (table 1 and 2). These included 
passive interventions such as provision of printed training manual about importance of 
ADR reporting; or the provision of active interventions including telephone interviews, 
educational workshops, lectures, email reminders, continuing medical education sessions, 
bulletins, visits to clinics, improving accessibility of the ADR reporting, group sessions and 
presentations (table 1 and 2).  
 
3.2.1.Technological interventions 
Three studies utilised electronic systems or features to increase accessibility of ADR 
reporting system or to prompt reminders about when to use the system for ADR reporting 
(table 1 and 2).  
 
3.2.2 Financial interventions 
Financial provisions used in the interventions included the use of lottery tickets, direct 
monetary rewards, and additional days off work (table 2).  
 
3.2.3 Policy interventions 
Two studies related to evaluation of the impact of new policies aimed at establishing 
responsibilities and methods for reporting ADRs (table 1 and 2).  
 
3.2.4. Mixed interventions 
Mixed nature of interventions were utilised in five studies including a mix of educational, 
financial, electronic system or policy interventions. A study [19] evaluated novel 
organisational policy for reporting adverse drug reactions by streamlining the process of 
reporting and incorporating ADR reporting mechanisms as part of the organisational 
accreditation documents. Two studies [20,21] focused on the improved regulation for 
reporting ADRs resulting from antibiotics use.  ADR reporting activity of health 
professionals was included in performance evaluation of the heads of hospital and 
department in one study [20] (table 1).  
 
3.3 Use of theory 
Only three studies used behavioural theory in the development of the intervention 
[25,38,40]. These studies used complacency; insecurity; diffidence; indifference; and 
ignorance to define key behavioural barriers and facilitators to reporting ADRs. The use of 
theory was deemed to have allowed the intervention to be designed to address these 
knowledge and attitude gaps (table 1).  
 
3.4 Intervention outcomes 
Almost all interventions apart from those utilising passive educational approaches showed 
improvement in the rate of reporting of spontaneous ADRs.  However, the unit of 
measurement and extent of improvement varied across the studies (table 2).  
 
3.4.1 RCTs 
All of the seven RCTs [25,27,30,31,34,38,40] included in the review used educational 
interventions. A study conducted in Portugal included a one hour educational visit by a 
pharmacist to hospital and community pharmacists as a group session to address the 
unmet educational need [38]. The study showed that over the 16 months period, adjusted 
increase in the total ADR reporting rate attributable to the intervention to be 275.63 per 
1000 pharmacist-years which accounted to a 5.87 fold (95% CI 1.98- 17.39, p=0.001) 
increase in reporting rate over 4 months post intervention. Improvement in the serious 
(10 fold), unexpected (4 fold), high-casualty (9 fold) and new drug-related ADRs (9 fold) 
were also observed. A sub-group analysis showed that the intervention had no effect on 
hospital pharmacists and any positive changes were seen only with community 
pharmacists [38]. Another study in Portugal by the same research group using similar 
cluster RCT design focused on the physicians using either telephone or workshop 
interventions [27]. Comparison with the control group showed that the workshop 
intervention increased the spontaneous ADR reporting rate by an average of 4-fold 
(relative risk [RR] 3.97; 95% CI 3.86, 4.08; p < 0.001) across the 20 months post 
intervention. Telephone interviews, in contrast was shown to prove less efficient since they 
led to no significant difference (p = 0.052) in the reporting rate and the intervention effect 
did not last long [27]. Another cluster RCT conducted in Portugal used either telephone 
interviews (4-12 minutes) or 1 hour workshop workshops to promote ADR reporting 
amongst hospital and community pharmacists [31]. Outcomes evaluated four months 
post-intervention showed improvement in ADR reporting rates and quality, although the 
effects declined over time (table 2).   
 
A cluster RCT conducted in Spain [25] which used an active component (group session 20-
25 minutes) and a passive component (educational material) to the physicians delivered 
by pharmacists. The intervention showed educational intervention increased ADR reporting 
by 65.4 % (95 % CI 8.2–153.4) over the four month period post intervention. Moreover, 
the educational intervention had a positive effect on the relevance of reporting, measured 
as the increase in unexpected reports (2.06, 95 % CI 1.19–3.55) (table 2). 
 
An RCT conducted in Sweden focused on the heads of primary healthcare units which 
consisted of email communications about the importance of reporting ADR showed no 
statistically significant effect on the quality or the quantity of ADR reports [34]. Another 
study in Sweden which used a one-page information letters on three occasions to 
physicians and nurses in primary healthcare unit did not show a significant increase in the 
ADR reporting rate (mean number of reports per unit ± standard deviation: 1.0 ± 2.5 vs. 
0.7 ± 1.2, P = 0.34), although increase in the number of high quality reports was noticed 
(table 2) [30].  
 
Five RCTs were included in meta-analysis [25,27,31,38,40].  Two RCTs [30,34]were 
excluded from meta-analysis because of following two reasons: Firstly, mode of delivery 
of educational interventions in these trials was passive and lacked face-to-face contact 
component. Combining interventions with different mode of delivery would have 
introduced clinical heterogeneity and is not recommended. Secondly, data were not 
reported in an appropriate format to allow meaningful statistical combination.  
The meta-analysis found a statistically significant 3.5-fold overall increase in reporting of 
ADRs [RR 3.53; 95% CI (1.77, 7.06)] in the intervention group compared to the control 
(figure 2). Furthermore, approximately a 4-fold increase was noted in reporting of serious 
ADRs [RR 4.18; 95% CI (1.69, 10.33)] and unexpected ADRs [RR 5.16; 95% CI (2.42, 
11.03)] in the intervention group compared to the control (figure 2).  
3.4.2 Other study designs 
 
A study in China demonstrated that financial interventions which constituted rewards and 
penalty led to 855% increase in the number of ADR reported [20]. When combined with 
additional regulation, the changes were augmented to over 2,000 fold increase. A 379% 
increase in the number of ADR reports were reported by a study on the financial incentives 
delivered to patients, pharmacists, physicians and nurses in Saudi Arabia [17] The 
intervention which consisted of employee of the month award for the most frequent 
reporter, letters of appreciation, extra annual leave and performance also led to increase 
in the number of serious ADR reporting. One study which used lottery tickets as an 
economic inducement showed 59% increase in the ADR reporting rate in the intervention 
group (p<0.10) [39] (table 2).  
The two studies utilising electronic reminders showed positive changes in ADR reporting 
rates and quality. One study [28] investigated electronic reminders to the electronic 
patient records or to the desktop computers. The hyperlink took participants to an online 
ADR reporting form. When comparing with the control group, a statistically significant 
improvement in reporting was noted. However, outcome follow up only lasted until 4 
months post-intervention. Another study [35] used an electronic system to facilitate ADR 
reporting through easy use, automatic input of certain information, and increased 
accessibility. A positive improvement in the reporting rate by both the physician and 
pharmacist study participants in the eight months post intervention period were observed 
(table 2). 
 
Changes in ADR reporting policy alone was shown to only minimally improve ADR reporting 
practices [19] despite the follow up evaluation was conducted only three months after the 
introduction of the new policy. Both studies focused on policy/regulatory interventions 
were specific to a particular clinical setting, Canadian Forces Health Services Group [19] 
and specific hospitals [21] in China. While one study [19] made a reference to a national 
policy change, evaluation was limited to the impact on a specific clinical setting (table 2).   
 
A study on the impact of mass public and health professional campaign on the ADR 
reporting conducted in Scotland showed an improvement in the reporting by members of 
public, however, the changes were reported to be insignificant [22]. Changes in the 
physician computer software systems implemented during the same period were deemed 
to have impacted on the observed positive changes. The comparator geography used in 
the evaluation was based outside of Scotland (table 2). 
 
In summary, evidence from non-randomised studies showed that interventions involving 
financial incentives as a standalone or combined with other interventions types often 
yielded the biggest changes in the ADR reporting rates. Financial interventions reported 
between 59% and 855% increase in ADR reporting (Table 2). Similar to the findings from 
RCTs, face-to-face educational interventions showed greater impact on the number and 
quality of ADR reported than those not involving face-to-face interactions (table 2).Limited 
impact was reported around the impact of policy interventions. Pharmacovigilance 
activities aimed at patients were able to produce limited changes in reporting practices.    
 
4.0 Discussion 
Spontaneous ADR reporting is key to improving the post-marketing safety of medicines 
and it is imperative to identify essential features of successful interventions that can be 
adopted widely. This is the first systematic review incorporating a meta-analysis of the 
impact of interventions to improve the quality and quantity of spontaneous ADR reporting 
considering both healthcare professionals and patients. A total of 28 studies were included 
in the review of which none of the studies satisfied all quality criteria. Most of the studies 
were small scale studies conducted within one specific hospital, clinical speciality or a 
region. There was a lack of a high quality large scale, multi-centre RCTs or pragmatic 
study designs. Although seven studies used RCT designs, none were assessed to have a 
low risk of bias. Contamination was likely to exist given communications amongst 
healthcare professionals across study settings and geography.      
 
A total of 14 included studies in this systematic review did not include any control group. 
These were often single arm before and after study designs and the results of these studies 
are less likely to be transferable to other settings. Where control groups were used, data 
were often collected on the total number and nature of ADRs from other geographical 
areas or other healthcare settings. There was often a lack of adequate data on the 
demographics, clinical characteristics and baseline awareness of spontaneous ADR 
reporting amongst participants.  
   
Most of the included studies included educational interventions to improve ADR reporting. 
A variety of educational methods were used including reminders, face to face educational 
sessions and newsletters. While most of these studies were reported to have improved 
ADR reporting, there was a lack of long-term follow up of the outcomes. The cluster-
randomised controlled trials included in the study reported that the impact of interventions 
observed by the difference in the intervention and control group in the ADR reporting rate 
lasted for only 12 months after which such difference was no longer significant. While 
transient impact is easy to realise, sustainability around change in behaviours is often 
difficult to achieve [45-48]. Interventions that have been designed with implementation in 
mind from the outset face least barriers to implementation. Capacity building, ongoing 
monitoring and evaluation and addressing political, contextual and behavioural barriers to 
implementation have been identified as key factors that can promote sustainability [46].   
 
4.1. Implications for practice and research 
While a number of evaluations were included in the systematic review, they only 
represented a very small number of countries. There is a scope to improve spontaneous 
ADR reporting in middle and low-and-middle income countries (LMIC) given the high 
contribution to global burden of diseases and increasing medicines use within those 
regions. Unique barriers may exist in LMICs which includes lack of a non-blame culture 
and professional hierarchy [24]. Hence in such settings, educational interventions alone 
may not be sufficient in changing practice.  
 
There is a scope to include community pharmacy, particularly to improve ADR reporting 
by patients. Community pharmacies are well distributed geographically and are easily 
accessible by population. For example in England, over 90% of population in England live 
within a 20-minutes’ walk to a community pharmacy and they are well situated to promote 
ADR reporting by patients [49,50].  Only five included studies used community pharmacy 
based interventions to improve ADR reporting, of which one only aimed to promote ADR 
reporting by patients. There is a scope for interventions aimed at patients to be developed, 
implemented and evaluated. Over a 100 countries have now provisions for ADR reporting 
by patients [51]. Despite this, a very low awareness amongst patients about their eligibility 
to report ADRs in eligible countries exist [52]. 
 
Interventions as well as outcomes measurement needs to be sustained over time. 
Continuing professional development models needs to be in place instead of one-off 
training events. Studies need to build needs assessment and implementation plans as part 
of the intervention development to promote sustainability.    
 
There was a lack of consideration of behavioural theories in intervention development. 
There is an accumulation of evidence that theory based interventions are more likely to 
yield positive and sustainable results compared to pragmatic approaches. There is 
therefore a need for a well-designed, systematic and comprehensive study of a 
theoretically derived intervention aiming to optimize ADR reporting by health professionals 
and patients. The Medical Research Council Framework of Complex Interventions in the 
UK advises the use of theory and exploratory studies to identify barriers to change while 
developing complex interventions [53]. It is imperative that future interventions utilise 
appropriate theories to maximise the success of interventions. These include the use of 
theoretical domains framework (TDF) [54] and behaviour change taxonomy (BCT) [55]. 
The various interacting components in behaviour change research makes them challenging 
to identify the active, effective components within interventions and for others to replicate 
them. The included studies in these systematic reviews often tend to report mean changes 
in ADR reporting rates across all participants. It will be worth considering the low or the 
non-reporters and developing and targeting active ingredients of the interventions to focus 
on the low and non-reporters.  
  
5.0. CONCLUSIONS 
The limited evidence showed that active interventions involving face to face educational 
approaches, financial incentives and electronic features targeted at healthcare 
professionals could improve ADR reporting. However, the results need to be interpreted 
cautiously given the short term evaluation outcomes, dominance of observational designs 
and low quality of included studies. While observational studies are allow pragmatic 
approach to undertaking pharmacovigilance interventional studies, there is a need to 
develop and test theory based interventions through fully powered randomised controlled 
trial design, particularly those including patients. Moreover, there is a need for 
interventions to be developed and tested in countries low-and-middle income countries.  
 
6. Expert opinion 
Most of the currently available interventional research studies in relation to improving ADR 
reporting have relied on educational interventions with measurements of transient 
outcomes. Future studies need evidence base from LMICs, particularly in relation to 
addressing policy level, professional, organisational and cultural barriers to spontaneous 
ADR reporting. While global policy changes allowing patients to report spontaneous ADRs 
have been welcome, research to capture impact and facilitators of greater patient 
involvement needs to be undertaken through the use of behaviour change theories.    
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Figure 2: Forest plots depicting effectiveness of interventions  to improve ADR reporting across three outcomes (Overall 






















Figure 1: Risk of bias assessment 
Legends not applicable 
 
Figure 2: Forest plots Forest plots depicting effectiveness of interventions to improve ADR reporting across three outcomes 
(Overall ADRs, Serious ADRs and Unexpected ADRs) 
Legends not applicable 
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2     adr report*.mp.   
3     adverse drug event$ report*.mp.   
4     side effect$ report*.mp.   
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6     improv*.mp.   
7     motivat*.mp.   
8     incentiv*.mp.   
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